Clinical potential of antibody-drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors
{{output}}
Recently, comprehensive genomic profiling (CGP)-matched therapy and antibody-drug conjugates (ADCs) have garnered increased attention. However, their response rates and prognoses in early-phase clinical trials are not yet widely appreciated in clinical practic... ...
